Boniva Labeling Reflects Class Osteonecrosis, Musculoskeletal Pain Risk

 
• By The Pink Sheet

Labeling for Roche/GlaxoSmithKline's once-monthly osteoporosis agent Boniva reflects upcoming class labeling for osteonecrosis and musculoskeletal pain risk with oral bisphosphonates

More from Archive

More from Pink Sheet